Role of interleukin-8 in radiotherapy resistance of non-small cell lung cancer and potential strategies for targeted therapy

Guan Yuting; Chen Ximing; Shi Chiyu

doi:10.13406/j.cnki.cyxb.004010

您当前的位置：

首页 >

文章列表页 >

Role of interleukin-8 in radiotherapy resistance of non-small cell lung cancer and potential strategies for targeted therapy

Precision medicine in cancer and translational studies | 更新时间：2026-04-15

- Role of interleukin-8 in radiotherapy resistance of non-small cell lung cancer and potential strategies for targeted therapy
- Journal of Chongqing Medical University Vol. 51, Issue 4, Pages: 516-521(2026)
- 作者机构：
  
  1.中国医科大学附属盛京医院放射治疗室，沈阳 110022
  2.中国医科大学附属盛京医院肿瘤多组学研究创新实验室，本溪 117004
  3.中国医科大学附属盛京医院放射科，沈阳 110022
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.004010
  CLC： R734.2
- Received：24 July 2025，
  
  Revised：2025-10-23，
  
  Accepted：13 November 2025，
  
  Published：28 April 2026
- 稿件说明：
移动端阅览
关宇廷，陈熹铭，石驰宇.IL-8在非小细胞肺癌放疗耐受性中的作用及潜在靶向策略[J].重庆医科大学学报，2026，51（4）：516-521.

Guan Yuting,Chen Ximing,Shi Chiyu.Role of interleukin-8 in radiotherapy resistance of non-small cell lung cancer and potential strategies for targeted therapy[J].Journal of Chongqing Medical University,2026,51(4):516-521.
关宇廷，陈熹铭，石驰宇.IL-8在非小细胞肺癌放疗耐受性中的作用及潜在靶向策略[J].重庆医科大学学报，2026，51（4）：516-521. DOI： 10.13406/j.cnki.cyxb.004010.

Guan Yuting,Chen Ximing,Shi Chiyu.Role of interleukin-8 in radiotherapy resistance of non-small cell lung cancer and potential strategies for targeted therapy[J].Journal of Chongqing Medical University,2026,51(4):516-521. DOI： 10.13406/j.cnki.cyxb.004010.

摘要

目的

探讨白细胞介素-8（interleukin-8，IL-8）通过调控FAS细胞表面死亡受体（FAS cell surface death receptor，FAS）/FAS细胞表面死亡配体（FAS cell surface death receptor ligand，FASL）通路在非小细胞肺癌（non-small cell lung cancer，NSCLC）放疗耐受性中的作用，并评估靶向IL-8信号通路作为改善放疗效果的潜在策略。

方法

利用酶联免疫吸附测定法检测放疗前后NSCLC患者血清中IL-8和可溶性FAS配体（soluble FAS ligand，sFASL）水平的变化，并使用IL-8受体抑制剂Repertaxin观察NSCLC细胞对放疗的敏感性变化，分析IL-8在FAS/FASL通路中的调控作用。

结果

放疗后患者血清中IL-8和sFASL水平均发生明显变化。放疗前3 d血清IL-8中位数为6.60 pg/mL，放疗后8周升至8.73 pg/mL，差异有统计学意义（

=0.033），提示IL-8水平在放疗后明显升高且持续时间较长。sFASL方面，放疗前3 d血清中位数为32.0 pg/mL，放疗后8周为161.4 pg/mL，差异

有统计学意义（

0.001）。提示IL-8通过抑制FAS/FASL通路降低肿瘤细胞凋亡，削弱放疗效果。Repertaxin处理后，NSCLC细胞在放疗48 h的凋亡率明显高于未处理组，表明阻断IL-8信号通路可增强肿瘤对放疗的敏感性。

结论

IL-8通过调控FAS/FASL通路促进NSCLC放疗耐受，靶向IL-8或CXC趋化因子受体1（C-X-C motif chemokine receptor 1，CXCR1）有望成为克服耐受、提高放疗疗效的新策略。

Abstract

Objective

To investigate the role of interleukin-8（IL-8） in radiotherapy resistance of non-small cell lung cancer （NSCLC） by regulating the FAS（FAS cell surface death receptor）/FASL（FAS ligand） pathway，and to assess the effect of IL-8 signaling pathway-targeted therapy in improving the efficacy of radiotherapy.

Methods

ELISA was used to measure the changes in the serum levels of IL-8 and soluble FAS ligand（sFASL） in NSCLC patients before and after radiotherapy. The IL-8 receptor inhibitor Repertaxin was used to observe the change in the sensitivity of NSCLC cells to radiotherapy，and the regulatory role of IL-8 in the FAS/FASL pathway was analyzed.

Results

After radiotherapy，the patients showed significant changes in the serum levels of IL-8 and sFASL. The median serum level of IL-8 increased from 6.60 pg/mL on day 3 before radiotherapy to 8.73 pg/mL at 8 weeks after radiotherapy（

=0.033），suggesting that there was a constant and significant increase in IL-8 level after radiotherapy. The median serum level of sFASL increased from 32.0 pg/mL on day 3 before radiotherapy to 161.4 pg/mL at 8 weeks after radiotherapy（

0.001）. IL-8 reduced tumor cell apoptosis and weakened the efficacy of radiotherapy by inhibiting the FAS/FASL pathway. The NSCLC cells treated with Repertaxin had a significantly higher apoptosis rate at 48 hours after radiotherapy than those without treatment，suggesting that blocking the IL-8 signaling pathway could enhance the sensitivity of tumor to radiotherapy.

Conclusion

IL-8 alleviates radiotherapy resistance in NSCLC by regulating the FAS/FASL pathway，and targeting IL-8 or C-X-C motif chemokine receptor 1 may become a new strategy to overcome resistance and enhance the efficacy of radiotherapy.

关键词

Keywords

references

Megyesfalvi Z ， Gay CM ， Popper H ， et al . Clinical insights into small cell lung cancer： Tumor heterogeneity，diagnosis，therapy，and future directions [J ] . CA Cancer J Clin ， 2023 ， 73 （ 6 ）： 620 - 652 ．

Yoshida D ， Kusunoki T ， Takayama Y ， et al . Comparison of dose distribution between VMAT-SBRT and scanning carbon-ion radiotherapy for early-stage NSCLC [J ] . Anticancer Res ， 2021 ， 41 （ 9 ）： 4571 - 4575 ．

郑保珍，汪雅芬，董智慧，等 . 放疗联合免疫治疗在局部晚期非小细胞肺癌中的疗效及安全性分析 [J ] . 系统医学， 2024 ， 9 （ 16 ）： 143 - 146，158 ．

Zheng BZ ， Wang YF ， Dong ZH ， et al . Analysis of the efficacy and safety of radiotherapy combined with immunotherapy in locally advanced non-small cell lung cancer [J ] . Syst Med ， 2024 ， 9 （ 16 ）： 143 - 146，158 ．

谢馥霞，李梦丹，王小会，等 . 18F-FDG PET/CT联合外周血炎症因子评估晚期非小细胞肺癌免疫治疗疗效的价值 [J ] . 现代肿瘤医学， 2023 ， 31 （ 17 ）： 3209 - 3215 ．

Xie FX ， Li MD ， Wang XH ， et al . Value of 18F-FDG PET/CT combined with inflammatory factors in peripheral blood in evaluating the efficacy of immunotherapy for advanced NSCLC [J ] . J Mod Oncol ， 2023 ， 31 （ 17 ）： 3209 - 3215 ．

Chen Y ， Gao M ， Huang ZQ ， et al . SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment： a focus on the mechanisms，advances，and future challenges [J ] . J Hematol Oncol ， 2020 ， 13 （ 1 ）： 105 ．

Brada M ， Forbes H ， Ashley S ， et al . Improving outcomes in NSCLC： optimum dose fractionation in radical radiotherapy matters [J ] . J Thorac Oncol ， 2022 ， 17 （ 4 ）： 532 - 543 ．

Yang JM ， Kumar A ， Vilgelm AE ， et al . Loss of CXCR4 in myeloid cells enhances antitumor immunity and reduces melanoma growth through NK cell and FASL mechanisms [J ] . Cancer Immunol Res ， 2018 ， 6 （ 10 ）： 1186 - 1198 ．

Sato Y ， Yoshino H ， Tsuruga E ， et al . Fas ligand enhances apoptosis of human lung cancer cells cotreated with RIG-I-like receptor agonist and radiation [J ] . Curr Cancer Drug Targets ， 2020 ， 20 （ 5 ）： 372 - 381 ．

Ginestier C ， Liu SL ， Diebel ME ， et al . CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts [J ] . J Clin Invest ， 2010 ， 120 （ 2 ）： 485 - 497 ．

Corrò C ， Healy ME ， Engler S ， et al . IL-8 and CXCR1 expression is associated with cancer stem cell-like properties of clear cell renal cancer [J ] . J Pathol ， 2019 ， 248 （ 3 ）： 377 - 389 ．

Kumar A ， Shalmanova L ， Hammad A ， et al . Induction of IL-8（CXCL8） and MCP-1（CCL2） with oxidative stress and its inhibition with N-acetyl cysteine （NAC） in cell culture model using HK-2 cell [J ] . Transpl Immunol ， 2016 ， 35 ： 40 - 46 ．

Mosleh-Shirazi MA ， Kazempour S ， Fardid R ， et al . Intra-fractional dose rate effect in continuous and interrupted irradiation of the MCF-7 cell line： Possible radiobiological implications for breath-hold techniques in breast radiotherapy [J ] . J Cancer Res Ther ， 2024 ， 20 （ 3 ）： 863 - 868 ．

Liu K ， Zhao XK ， Gu J ， et al . Eff ects of 12 C6+ heavy ion beam irradiation on the p53 signaling pathway in HepG2 liver cancer cells [J ] . Acta Biochim Biophys Sin ， 2017 ， 49 （ 11 ）： 989 - 998 ．

Singh S ， Wu S ， Varney M ， et al . CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation，migration and capillary-like structure formation [J ] . Microvasc Res ， 2011 ， 82 （ 3 ）： 318 - 325 ．

Koshkina N ， Yang YZ ， Kleinerman ES . The fas/FasL signaling pathway： its role in the metastatic process and as a target for treating osteosarcoma lung metastases [J ] . Adv Exp Med Biol ， 2020 ， 1258 ： 177 - 187 ．

Singh JK ， Simões BM ， Howell SJ ， et al . Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells [J ] . Breast Cancer Res ， 2013 ， 15 （ 4 ）： 210 ．

Brandolini L ， Cristiano L ， Fidoamore A ， et al . Targeting CXCR1 on breast cancer stem cells：signaling pathways and clinical application modelling [J ] . Oncotarget ， 2015 ， 6 （ 41 ）： 43375 - 43394 ．

Matsumoto N ， Imamura R ， Suda T . Caspase-8- and JNK-dependent AP-1 activation is required for Fas ligand-induced IL-8 production [J ] . FEBS J ， 2007 ， 274 （ 9 ）： 2376 - 2384 ．

Ariyoshi K ， Miura T ， Kasai K ， et al . Radiation-induced bystander effect is mediated by mitochondrial DNA in exosome-like vesicles [J ] . Sci Rep ， 2019 ， 9 （ 1 ）： 9103 ．

Tang HY ， Cai LW ， He XY ， et al . Radiation-induced bystander effect and its clinical implications [J ] . Front Oncol ， 2023 ， 13 ： 1124412 ．

Wang R ， Zhou TY ， Liu W ， et al . Molecular mechanism of bystander effects and related abscopal/cohort effects in cancer therapy [J ] . Oncotarget ， 2018 ， 9 （ 26 ）： 18637 - 18647 ．

Zhang C ， Liang ZZ ， Ma SM ， et al . Radiotherapy and cytokine storm： risk and mechanism [J ] . Front Oncol ， 2021 ， 11 ： 670464 ．

Najafi M ， Fardid R ， Hadadi G ， et al . The mechanisms of radiation-induced bystander effect [J ] . J Biomed Phys Eng ， 2014 ， 4 （ 4 ）： 163 - 172 ．

Kurenova E ， Xu LH ， Yang XH ， et al . Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein [J ] . Mol Cell Biol ， 2004 ， 24 （ 10 ）： 4361 - 4371 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Radiotherapy combined with immunotherapy in treatment of driver gene-negative non-small cell lung cancer: updates and challenges

An analysis of hot issues in immunotherapy for non-small cell lung cancer

Expert consensus on perioperative treatment decision-making for stage I non-small cell lung cancer

Correlation of homologous recombination repair genes with clinical features in non-small cell lung cancer

Related Author

Shi Chiyu

Chen Chuan

Du Jia

Li Mengxia

Zhang Zhimin

Zhang Bicheng

Sun Jianguo

Li Mengxia

Related Institution

Department of Oncology，Daping Hospital，Army Medical University

Cancer Center，Renmin Hospital of Wuhan University

Department of Oncology，The Second Affiliated Hospital of Army Medical University

Department of Oncology， PLA Army Characteristic Medical Center

Department of Oncology，Guizhou Provincial People’s Hospital

⁰